What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
His primary areas of study are Internal medicine, Surgery, Randomized controlled trial, Hazard ratio and Oncology.
His Internal medicine research includes elements of Gastroenterology and Diabetes mellitus, Endocrinology.
He has researched Surgery in several fields, including Stroke, Adverse effect and Confidence interval.
His Randomized controlled trial study also includes fields such as
- Clinical trial and related Tolerability,
- Placebo which is related to area like Clinical endpoint and Oral administration.
The various areas that Yasuo Ohashi examines in his Hazard ratio study include Cancer and Gemcitabine.
His Oncology course of study focuses on Meta-analysis and Linear regression, Relative risk, Physical therapy and Disease.
His most cited work include:
- Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women: A Meta-analysis (1701 citations)
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (1677 citations)
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer (795 citations)
What are the main themes of his work throughout his whole career to date?
Yasuo Ohashi mostly deals with Internal medicine, Oncology, Surgery, Randomized controlled trial and Breast cancer.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Diabetes mellitus.
While the research belongs to areas of Diabetes mellitus, Yasuo Ohashi spends his time largely on the problem of Incidence, intersecting his research to questions surrounding Prospective cohort study.
His Oncology study combines topics from a wide range of disciplines, such as Cancer, Colorectal cancer, Irinotecan, Adjuvant therapy and Quality of life.
His studies deal with areas such as Placebo, Adverse effect and Cohort study as well as Surgery.
His work deals with themes such as Cyclophosphamide and Docetaxel, which intersect with Breast cancer.
He most often published in these fields:
- Internal medicine (73.57%)
- Oncology (31.71%)
- Surgery (20.29%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (73.57%)
- Oncology (31.71%)
- Breast cancer (16.43%)
In recent papers he was focusing on the following fields of study:
Yasuo Ohashi spends much of his time researching Internal medicine, Oncology, Breast cancer, Randomized controlled trial and Hazard ratio.
His Internal medicine study frequently draws connections between related disciplines such as Cardiology.
His Oncology research is multidisciplinary, incorporating elements of Quality of life, Cohort and Phases of clinical research.
His Breast cancer study integrates concerns from other disciplines, such as Cyclophosphamide and Adjuvant therapy.
The concepts of his Hazard ratio study are interwoven with issues in Diabetes mellitus, Type 2 diabetes, Incidence and Proportional hazards model.
His Clinical trial research is multidisciplinary, relying on both Observational study and Prospective cohort study.
Between 2016 and 2021, his most popular works were:
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. (427 citations)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)
- Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project (161 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His primary areas of investigation include Internal medicine, Oncology, Hazard ratio, Randomized controlled trial and Breast cancer.
His study in Diabetes mellitus extends to Internal medicine with its themes.
His study in Oncology is interdisciplinary in nature, drawing from both Regimen, Epidermal growth factor receptor, Survival analysis and Phases of clinical research.
His studies examine the connections between Hazard ratio and genetics, as well as such issues in Proportional hazards model, with regards to Nephrology, Kidney disease, Diet therapy, Malnutrition and Mortality rate.
Yasuo Ohashi works mostly in the field of Breast cancer, limiting it down to concerns involving Adjuvant therapy and, occasionally, Paclitaxel.
His Incidence research integrates issues from Body mass index, Endocrinology, Cohort study and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
